Therapeutic Peptides for Healthy Aging: What a 2026 Gerontology Review Means for Patients

If you've been researching peptide therapy for longevity, tissue repair, or metabolic health, a significant new review published in *Frontiers in Aging* offers the most comprehensive academic snapshot to date of where the science actually stands. Authored by Mavrych, Shypilova, and Bolgova (2026), this narrative review systematically evaluates nine therapeutic peptides across multiple aging hallmarks — and it arrives at conclusions that are both encouraging for patients and appropriately cautious about what we still don't know.

As a physician specializing in peptide therapy and longevity medicine, I find this paper valuable precisely because it doesn't overstate the evidence. It maps out what's proven, what's promising, and where rigorous clinical trials are still urgently needed.

**Citation type:** Comprehensive narrative review

**Source databases:** PubMed, Scopus, FDA and WADA regulatory documents

**Search window:** Inception through January 2026

**Primary sources evaluated:** 20 peer-reviewed articles, clinical trials, and regulatory documents

**Peptides reviewed:** Tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, bremelanotide

**Published:** April 7, 2026 | *Frontiers in Aging* | DOI: 10.3389/fragi.2026.1790247

The authors framed their inquiry around the fundamental hallmarks of aging — metabolic dysfunction, telomere attrition, impaired tissue repair, and hormonal decline — and asked which peptides have demonstrated measurable effects on these biological targets.

This review matters because it draws a clear, evidence-based line between what is clinically established and what remains investigational. That distinction is essential in a field where marketing often runs ahead of the science.

For FDA-approved peptides like tirzepatide, physicians now have large-scale trial data to draw on when counseling patients about metabolic aging interventions. For investigational peptides such as BPC-157, TB-500, and epitalon, the preclinical signal is genuinely interesting — but the authors are correct that well-designed, long-term human trials are what the field needs most.

The review also underscores that peptide therapy is not a monolithic category. Each peptide acts through distinct mechanisms, targets different tissues, and carries its own evidence profile. A responsible clinical approach means evaluating each agent individually and matching it to a patient's specific physiology, goals, and risk tolerance.

If you are considering peptide therapy for longevity, recovery, or metabolic health, this review reinforces several principles I apply in my own clinical practice:

**Evidence hierarchy matters.** Not all peptides are created equal in terms of clinical validation. Asking your physician about the quality of evidence behind any peptide you're considering is entirely appropriate.

**Mechanism specificity is a feature, not a bug.** The fact that these nine peptides target different hallmarks of aging means that thoughtful combination protocols — when grounded in individual assessment — may offer synergistic benefits. But that also means generic, one-size-fits-all protocols are inadequate.

**Monitoring is non-negotiable.** The authors specifically call out the lack of validated biomarkers as a major gap. In my practice, I use baseline and follow-up labs to track objective markers of response, not anecdote.

**Investigational status requires informed consent.** Peptides outside FDA approval are not inherently unsafe, but patients deserve a frank conversation about what the evidence does and does not show.

The authors themselves acknowledge several important constraints: